#1KHIRON LIFE SCIENCES CORP A PATIENT-FOCUSED, GLOBAL CANNABIS COMPANY FROM LATIN AMERICA TSXV: KHRN | OTCQX: KHRNF | FRANKFURT: A2 JMZC July 2020#2KHIRON LARI Legal Notices This information in this presentation is current as of April 1, 2020 unless otherwise indicated. The information contained in this presentation is provided for informational purposes only and does not constitute an offer to issue or arrange to issue, or the solicitation of an offer to issue, securities of Khiron. No part of this presentation shall form the basis or be relied upon in connection with any contract, commitment or investment decisions in relation thereto. The information contained herein is not investment advice and is not intended to be used as the basis for making an investment decision. No securities commission or similar regulatory authority in Canada has reviewed this presentation. Investors and prospective investors should rely only on the information contained in the continuous disclosure filings of Khiron on www.SEDAR.com under Khiron's issuer profile. This presentation is qualified in its entirety by reference to, and must be read in conjunction with, such filings. This presentation contains "forward-looking statements," within the meaning of applicable Canadian securities laws. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations, assumptions and analyses made by us regarding the future of our business, future plans and strategies, our operational results and other future conditions. These forward-looking statements appear in a number of places throughout this presentation and can be identified by the use of words, such as "anticipates," or "believes," "budget," "estimates," "expects," or "is expected," "forecasts," "intends," "plans," "scheduled," or variations of such words and phrases or state that certain actions, events or results "may," "might," "will," "would," "could", "should," "continue," or be taken, occur or be achieved. These forward-looking statements relate to, among other things, our future financial performance, financial condition, liquidity, levels of activity, performance, prospects, growth, goals or achievements or other future events. Although we base the forward-looking statements contained in this presentation on assumptions that we believe are reasonable, these forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual performance and financial results in future periods to differ materially from those anticipated in our forward-looking statements, including those risk factors identified in Khiron's most recent MD&A, AIF and other disclosure documents available on SEDAR at www.SEDAR.com under Khiron's issuer profile. Forward- looking statements do not take into account the effect that transactions or non-recurring or other special items announced or occurring after the statements are made have on our business. For example, they do not include the effect of asset impairments or other charges announced or occurring after the forward-looking statements are made. The financial impact of such transactions and non-recurring and other special items can be complex and necessarily depends on the facts particular to each of them. Despite a careful process to prepare and review the forward-looking statements, there can be no assurance that the underlying opinions, estimates, and assumptions will prove to be correct. The purpose of the forward-looking statements is to provide the reader with a description of management's expectations regarding our anticipated future performance and may not be appropriate for other purposes. Furthermore, unless otherwise stated, the forward-looking statements contained in this report are made as of the date of this report and we do not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise unless required by applicable legislation or regulation. The forward-looking statements contained this document are expressly qualified by this cautionary statement. Market Research and Public Data: This corporate presentation also contains or references certain market, industry and peer group data which is based upon information from independent industry publications, market research, analyst reports and surveys and other publicly available sources. Although we believe these sources to be generally reliable, such information is subject to interpretation and cannot be verified with complete certainty due to limits on the availability and reliability of raw data, the voluntary nature of the data gathering process and other inherent limitations and uncertainties. We have not independently verified any of the data from third party sources referred to in this presentation and accordingly, the accuracy and completeness of such data is not guaranteed. Future Oriented Financial Information: To the extent any forward-looking information in this corporate presentation constitutes "future-oriented financial information" or "financial outlooks" within the meaning of applicable Canadian securities laws, such information is being provided to demonstrate the anticipated market penetration and the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such future-oriented financial information and financial outlooks. Future- oriented financial information and financial outlooks, as with forward-looking information generally, are, without limitation, based on the assumptions and subject to the risks set out above. Our actual financial position and results of operations may differ materially from management's current expectations and, as a result, our revenue and profitability may differ materially from the revenue and profitability profiles provided in this corporate presentation. Such information is presented for illustrative purposes only and may not be an indication of our actual financial position or results of operations. Use of Non-GAAP Measures: This document refers to certain financial performance measures that are not defined by and do not have any standardized meaning under GAAP and are used by management to assess the financial and operational performance of the Company, including EBITDA, because certain investors may use this information to assess our performance and also determine our ability to generate cash flow. This data is furnished to provide additional information and are non-GAAP measures and do not have any standardized meaning prescribed by GAAP. They should not be considered in isolation as a substitute for measures of performance prepared in accordance with GAAP and is not necessarily indicative of operating costs presented under GAAP.#3KHIRON is a pureplay health & wellbeing company in the rapidly growing global cannabis market Our Mission Verenia DDD To improve the quality of life of patients and consumers through the applied use of cannabis 1st company to begin sales of medical cannabis in Colombia, combining a traditional pharma approach, wholly-owned clinics and telehealth solutions 1st company approved to cultivate up to 9.3 tonnes of High-THC cannabis in Colombia 11 SKUs of CBD-based CPG products in over 3 continents 2 Our Vision DDD To reach 1 million patients and consumers by 2024 KHIRON LITT SEITACTS CORE Over 150,000 patient transactions in own clinics, including medical cannabis patients First medical cannabis scripts of High-THC in the UK, in Q2 2020 First medical cannabis sales in Germany, projected for Q3 2020#4Khiron's Market Opportunity Medical Cannabis 86.0 $28.9 Million Patients US$ Billion KHIRON 18,0 68,0 $22,3 $6,6 Patients Market (Million Patients) (US$ Billions) in 2024 LatAm Europe KHIRON MED Sources: Prohibition Partners Global Cannabis Report, Nov 2019, European Cannabis Report, 5th Edition. Mgmt estimates on patient base % Potential Patients by Condition in Latin America 3 Unique approach to patient acquisitions by focusing on relationships & education 12% 8% 9% 17% --53% Chronic Pain Depression Other Sources: Management own estimates by IMS Quantiles Anxiety Epelepsy KHIRON Prasaden KHIRON Ir SciTNCS CORP பண்டை * de Magd tow KHIRON Preparación Magistral SERGE 45524#5B2C Focus: Brands, not grams 01/01/2011 K X →Starbucks USD/share Source: Finance Yahoo SBUX, https://www.macrotrends.net/2535/coffee-prices-historical-chart-data KHIRON LIFE SCIENCES CORP -O-Coffee Spot Price (USD/Lb) 个 255% $ 65.7/share 01/01/2012 01/01/2013 01/01/2014 01/01/2015 01/01/2016 01/01/2017 01/01/2018 01/01/2019 ABUCK COFFEL ↓ 54% $ 1.2/Lb#6Go to Market Medical Strategy KHIRONMED P 00 Locatel nimbus HEALTH OND ✓ High quality medical cannabis products Stabilized and consistent with multiple concentration ratios and presentations ✓ Doctor education to drive prescriptions Generating brand loyalty and awareness by continuously engaging to educate doctors everywhere KHIRON LIFE SCIENCES CORP ✓ Wholly-owned clinics Owning or partnering exclusively with 3rd party clinics for direct patient access, data, and business analytics to generate evidence Khiere ✓ Khiero patient program ✓ Accessible telehealth for all Telehealth platforms to access more doctors and patients in the low-touch economy Safe follow-up for treatment of patients to ensure adherence and brand loyalty VERPO ✓ Focus on distribution Partner early with established distributors / pharmacies to ensure accessibility 01 5 ESPIR#7A Path Towards Global Growth Colombia (К Peru 903 * Medical Cannabis Sales / Prescription Brazil 2 Health Services / Doctor Training Mexico 6 K Germany United Kingdom K Spain Kuida CBD CPG Sales KHIRON LIFE SCIENCES CORP K#81st Company to Prescribe and Sell Low and High-THC Medical Cannabis in Colombia 49.1 M Population * Production 5 Ha cultivation site in Colombia, including 14,000 sq. ft INVIMA GMP-GEP compliant extraction facility US$ 1.6B Colombia medical cannabis TAM¹ Education KHIRON MED 00 O Online physician and doctor education platforms to bring awareness and drive prescriptions CN2 5.6 Million Current patients with applicable conditions² Prescriptions 7 KHIROND Zerenia Numero de te Our clinics, with more than 150,000 patient transactions* & Telehealth solutions for online prescriptions CON CANNABIS MEDICINAL AGENDA TU CITA MEDICA O TELECONSULTA LLAMANDO A 300 412 8179-301 283 5413 CUERPO MENTET ESPIRITU KHIRON LIFE SCIENCES CORP US$ 370 / yr Estimated annual patient out-of-pocket expenditure on medical cannabis³ Distribution Locatel Agota 1-New Frontier Data. The Latin America Regional Cannabis Report 2019 Industry Outlook, 2- Mgmt estimates from IMS Quantiles study, 3- Mgmt own estimates Medical transactions include: consultation, surgical procedure, therapeutic support, diagnostic service, etc arado po IRON ENCES CORP Partnerships with 3rd party pain clinics and pharmacies for easy dispensation to patients#9Strategic Focus on Patients & Doctors Khiron's products are manufactured in INVIMA GMP-GEP compliant facilities in Colombia, and are standardized and stabilized according to the U.S. Pharmacopeia analytics standard (USP42) */ KHIRON pipe S Rich CBD 30 mg/ml KHRON Pracerseide han 1:1 (THC:CBD) 25 mg/ml 300 8 KHRON Presereder Magistral Rich THC 20 mg/ml 18% KHRON O 12% wapwan Nastal 70% * KHIRON Ir ScirCS CORP Preparac Nagistral CBD 50 ml - 100 mg/ml Khiron's actual medical cannabis patients in Colombia since April 2020 Pain & Paliative Care ■ Mental Health (Anxiety, Depression, Sleep) ■ Neurology & Epilepsy#10World-class Operations & Supply Chain Cultivation & Extraction Fully licensed for commercial THC and CBD cultivation, extraction & sales in Colombia Total area of 20 Ha. Current cultivation area of 80,000 sq.ft. Obtained 17% of Colombia's total allocation of THC quotas for 2020. 1st company to do so in Colombia State-of-the-art, 14,000 sq.ft. GMP-compliant post-harvest facility in Doima, Colombia (157 Km west of Bogota) Production Capacity3 Cultivation: Upwards of 9 tonnes¹ of dry flower Extraction: Up to 3 tonnes of full-spectrum extract², with capacity to expand within building ~1 MW Solar Park resulting in up to 40% energy cost reduction 1- Mgmt estimations @ stability of crops, 2-Based on management estimates, 3- Define as infrastructure & equipment max production capacity 9 Phase 2 & 3 6 Ha (645,000 SQ. FT) Phase 1B 80,000 SQ.FT#11Khiron Health Services: Direct Patient Access 4 ILANS ARNI Compre Aqu MINT. exp tel Zerenia Patient Data for Cannabis Product Development Pharmacy for Dispensing Medical Cannabis Pain Clinic Sleep Clinic Respiratory Recovery Neurology Palliative care 150,000 patient transaction in 2019* 8,000 prescriptions per month** *Medical transactions include: consultation, surgical procedure, therapeutic support, diagnostic service, etc. ** Refers to all medications prescribed, including opioids or other OTC medications 10 Comprehensive Suite of Services Including Medical Cannabis KHIRON LIFE SCIENCES CORP Mental Health Epilepsy and abnormal movements 3 locations in Bogota Gait laboratory Integrative Health 21 medical cannabis specialists trained 34 Insurance company clients US$ 6.9M Service revenues in 2019 KHIRON HEALTH SERVICES ILANS Zerenia SME#12Khiron's Approach in the Low Touch Economy Zerenia Dr. Zerenia Maria Naci Rapidly adopted telehealth and online services for everyone's safety in a post COVID-19 world ¡Estás a punto de descubrir los beneficios de tener atención médica con especialistas sin salir de casa! Conoce nuestro servicio de Teleconsulta. CONOCE MÁS Términos y Condiciones Ⓒ://khiran-khir-qafinebazapp.com/p//video/ME_Cytoque MACC 2 ng's New The Empieza ahora se Ha Lampa UL FOEFL RATE .. im Big one another Out Loud CEPAGO INGLES GET IT ON Download on the App Store Google Play PRÓXIMAMENTE APP Do $ Zerenia 3Datos de salud Cacha Ⓒ#711 1 O REGISTRO INGRESAR Gen (0) Marta Naranjs Paciente Maria Emma Naranjo WELCOME TO YOURTUAL POTENT Online doctor education Online medical appointment Web-based or App-based Online medical prescription E-payment platforms Home delivery of medical cannabis http://doctorzerenia.com 11 11:51 A App Store Dr Zerenia Dr. Zerenia Settings www. adalal Ana 9 12 11 KHIRON HIT SCIENCES CORP 2 2 76 5 Clock C all 4G Stocks 233 M#13Medical Education to Drive Prescriptions Medical education is a continuous process, ensuring we connect doctors with patients in all our markets 6 Partnerships with medical associations in 2019 1,500 Physicians can be trained online through partnership with Tec of Monterrey (LatAm's 3rd most prominent university, No. 1 in Mexico) Cenal de Cantabsencial TEATRING I Tecnológico de Monterrey COMO DE DAHRPELE EDICINAL 21 Kot so slaba wak KHIRON New product development Clinical & observational trials 12 Partnerships with medical associations KHIRON MED Recurring patients Zerenia CLINICA DE CUIDADO INTEGRADO KHIRON LIFE SCIENCES CORP Engage doctors in online education platforms Zerenia Clinic internships & observers Prescribing doctors#14Latin America Leader Brazil Peru 210 Million Population ● ● US$ 4.7B Brazil medical cannabis TAM¹ 32 Million Population US$ 250M Peru medical cannabis TAM² >24 Million potential patients³ 01/2020: Khiron obtains approval for compassionate care product import into Brazil by ANVISA 04/2020: Khiron closed deal with Medlive, a distributor serving 3,000 Clinics and Hospitals in the south of Brazil >3 Million potential patients³ 13 KHIRON LIFE SCIENCES CORP US$ 405/y Estimated annual patient out-of- pocket expenditure on medical cannabis US$ 317/y Estimated annual patient out-of- pocket expenditure on medical cannabis 03/2020: Signs 2-year agreement with Farmacia Universal (10 locations) for product manufacture and distribution 04/2020: Khiron obtains 1st license to import medical cannabis products into Peru 1-New Frontier Data - THE LATIN AMERICA REGIONAL 2019 INDUSTRY OUTLOOK, 2- Mgmt Estimates, 3- Mgmt estimates from IMS Quantiles#15Khiron Enters the UK with Project Twenty21 On May 6th, 2020 Khiron announced the Company received its first medical cannabis prescription in the UK. Khiron is the exclusive Latin American Company participating in the project. 66.4 M population United Kingdom US$ 1.3 Billion TAM Medical cannabis 2024 ¹ ● .... * .... Europe's 1st & largest national medical cannabis registry (Chronic pain, epilepsy, PTSD, MS, Substance Abuse, Anxiety) 400,000 Medical cannabis patients by 2024¹ Treatments provided at clinics in the UK. or through doctor prescription Create evidence for the effectiveness and tolerability of medical cannabis in UK Drug Science Goal to reach 20,000 patients by end of 2021 Dy RE 1- Prohibition Partners - The UK Cannabis Report, January 2020 RC PSYCH ROYAL COLLEGE OF PSYCHIATRISTS 7.3 Million People use CBD in the UK every year¹ 14 THE BRITISH PAIN SOCIETY EXPERTISE WHERE IT MATTERS KHIRON LIFE SCIENCES CORP PLEA For Quality of Life with Medical Cannabis#16III and Germany, largest market opportunity in Europe "Khiron Signs Distribution Deal in Germany for Medical Cannabis Imports and Sales" - June 25th, 2020 82.8 M population 50% of total medical cannabis sales in March 2020 are dry flower sales¹ US$ 8.7 Billion Germany TAM medical cannabis by 2028² US$ 43.9 M Reimbursements for medical cannabis in Q1 2020¹ 78,233 Prescriptions in Q1 2020¹ 1.0 Million Patients by 2024¹ 158% 16% 1- https://mjbizdaily.com/insurance-covered-reimbursements-for-medical-cannabis-sets-record-in-germany/, 2- Prohibition Partners - The Germany Cannabis Report, October 2019 nimbus HEALTH Marketing & Medical Distribution Education 15 KHIRON LIFE SCIENCES CORP % Patients by condition in Germany Anorexia 10% 8% 11% 71% Chronic Pain Spasticity Other#17Focused on Consumers and Distribution BELA KUIDA KHIRON WELLBEING 1- Technavio Research, February 2020 ● ● ● KHIRON KUIDA CANNABIS COSMECEUTICS Hemp-derived CBD for your skin! CBDERM WE DO IT DIFFERENT Launched in Q4 2018 in Colombia 11 SKUS, sold in 3 continents & 4 countries K KUIDA SMART 30% of sales through digital channels (Starting in May 2020) Q1 2020 sales increase of 18% compared to Q1 2019, with a GM of ± 60% 16 S KUIDA - www KUIDA KON KUIDA US$ 3.1 Billion 2024 CBD-infused cosmetics market¹ KHIRON UTT 36 TEST & GORF K KUIDA 11 H KUIDA FOLAT BELAJANTE SIDY MALT FEL THAT SWAR kuidaskincare.com (UYDA (UIBA#18Sustainability Matters COVID-19 RESPONSE 1) Provided the city of Bogota with a equipment to city's testing PCR testing increase the capabilities 2) Partership with accredited lab to process rapid and definitive testing across Bogota, including home testing ENVIRONMENT SOLAR PARK, DOIMA-IBAGUE 1) Implementation of recycling programs on substrate and irrigation to reduce waste 2) Delivery of packing material of site consumables to the community for recycling ~1MW UP TO 40% Energy Cost Reduction 17 KHIRON LIFE SCIENCES CORP SOCIAL RESPONSABILITY KHIRON 1) Donated nutritional kits to vulnerable families around our production site 2) Delivered medical supplies for the town's medical cente 3) Working alongside Alas de Emprendimiento, an ONG focused on vulnerable women, for recycling of Kuida stands and production of Kuida packaging items AMER OG ¿No funciono? NEXT dod#19A diverse, experienced management team Wendy Kaufman CFO, CPA 20 years of international financial experience, within Latin American and European operations. Experienced positions as CFO at Pasinex Resources Limited, Primero Mining Corporation, and Vice President, Finance and Treasury at Inmet Mining Corporation. Alvaro Torres CEO Andres Galofre VP Business Development 15+ years of leadership experience in pharmaceutical marketing, brand management, and distribution of ethical drugs and consumer products in Latin America. Led Advil launch in Colombia that reached 30% of domestic market share from inception Industrial Engineer (RPI), MBA (Georgetown University) 15+ years experience in top management of infrastructure sector in LatAm. Formerly with SNC-Lavalin building company's presence in Colombia. Overseen more than US$ 1 Billion infrastructure projects in development and completion Rodrigo Duran VP Khiron Med 17 years of experience in CPG & Pharma marketing, sales and go-to-market strategies, managing teams, and bringing brands across the Latam markets. Former manager executive of Team Food, Pfizer and Wyeth. ● Elsa Navarro VP, Khiron Wellbeing & Marketing ● More than 13 years of experience in international business, CPG marketing, brand management for international brands in skin care, personal care and other CPG categories Matt Murphy VP Compliance 25 years with the U.S. DEA. Served in variety of positions, including Chief of Pharmaceutical Investigations, prior to founding the Pharma Compliance Group. 18 Tejander Virk President, Khiron Europe 15 years of executive-level experience in the capital markets and cannabis industry. KHIRON LIFE SCIENCES CORP Rayad Harb VP, Khiron Health Services + 20 years of experience in operations management, administration and technology, With extensive experience in the executive management of healthcare companies, on both segments: health insurance and healthcare delivery services; CEO Sanitas USA, President Sanitas Mexico, VP Colsanitas ● Previously served as a Managing Director in Europe, for Canopy Growth Corp. Formerly Managing Director of Global Equity Products for BMO Capital Markets. Juan Diego Alvarez VP Regulatory Affairs Ph.D., Law and public health, Tulaine University 15+ years experience in top management of infrastructure sector in LatAm. Formerly with SNC-Lavalin building company's presence in Colombia. Overseen more than US$ 1 Billion infrastructure projects in development and completion . Franziska Katterbach CLO Khiron Europe 7 years of legal and regulatory expertise working within Europe's emerging cannabis industry. Previously working for Dentons involved in high profile cannabis deals across multiple jurisdictions. Later served as Legal Director for Canopy's European operations.#20Experienced Independent Board of Directors Global Branding, Project and Regional Business Expertise Chris Naprawa Chairman of the Board HIRO 20+ years of experience in institutional capital markets. Former partner at Sprott Capital Partners, Head of Equity Sales at Macquarie Canada, Head of Equity Sales and Trading at Dundee Securities and Managing Director at Primary Capital. Deborah Rosati Lead Director Over 30 years of experience, including in consumer, cannabis, private equity and venture capital. ● Vice Chair & Chair of the Audit Committee at cannabis authority Lift & Co (TSXV: LIFT). Former Chair of the Audit Committee at Sears Canada Inc., member of the Department Audit Committee at Correction Services Canada, and former Board member and Chair of the Audit Committee. at NexJ Systems Inc.. Alvaro Yañez Independent Director 15 years of legal experience in Colombia and internationally. 19 KHIRON Ir ScirCS CORP Alvaro Torres Co-founder & Director Industrial Engineer who built infrastructure projects in Colombia and LatAm. Formerly with SNC Lavalin and successfully built an engineering and merchant banking firm. Former Legal Manager of Frontera Energy (formerly known as "Pacific Exploration and Production"). Vicente Fox Independent Director Mexican businessman and politician who served as 55th President of Mexico. Former CEO Coca-Cola Mexico.#21Capital Structure & Coverage DREAM UNLIMITED CORP (DRM) 09.90 0.00 TMX. Notes: 1) As at July 8, 2020 2) Fully Diluted as for Nov 25, 2019 3) As at March 31, 2020 DESCARTES SYSTEMS GROUP INC (DSG) 0 39.23 0.00 Khiron Life Sciences Khiron Life Sciences TSXV: KHRN THE MARKET IS OPEN TMX TMX ENCANA CORPORATION (E 0 16.07 0.00 ANALYST COVERAGE TMX Basic Shares Outstanding¹ Recent Share Price (CAD)¹ Current Market Capitalization (CAD)¹ Aligned Management and Board² Warrants, Options and RSU's Outstanding (CAD) Weighted Average Strike Price for Warrants (CAD) ³ Cash (CAD)³ Total assets minus goodwill & intangible (CAD) ³ 3 FIRM AltaCorp Capital Bryan, Garnier & Co. 20 ANALYST David M. Kideckel Nikolaas Faaes KHIRON LIFE SCIENCES CORP 117.5 million $0.52 $61 million 20% 11.7 million $2.09 $24.4 million $50.3 million#22Investment Highlights + KHIRON LIFF SCIENCES CORP Estres Pureplay health & wellbeing company in the rapidly growing GLOBAL cannabis market Proven leader with first mover advantage Anchored by traditional clinical operations in Colombia for patient acquisition Low-cost and quality focused operations balanced with a diversified supply chain worldwide Major infrastructure, cultivation, extraction, labs and clinics built out Commercial sales of medical cannabis in 3 countries 000 21#23FLANS KHIRON LIFE SCIENCES CORP Visit Khiron online at investors.khiron.ca and on Instagram @khironlife 22 Alvaro Torres CEO Bogotá, Colombia Tel: +57 (320) 4950326 Email: [email protected] Chris Naprawa Chairman Toronto, ON, Canada Tel: +1 (416) 705-1144 Email: [email protected] [email protected] Tejinder Virk E.U President London, UK Tel: +44 (0) 79127-41995 Email: [email protected]